Objective: To assess the effect of intrathecal baclofen on spastic dysarthia in cerebral palsy.
Design: Single case study.
Methods: Functional outcome measures, including the Assessment of Intelligibility of Dysarthric Speech, were performed before and after a trial of intrathecal baclofen in an adult patient with spastic dysarthria due to cerebral palsy. The patient proceeded to intrathecal baclofen pump implantation and was reassessed after six months of continuous intrathecal baclofen therapy.
Results: Improvement in function including speech intelligibility was seen following the intrathecal baclofen trial. The improvement was sustained at six months post pump implantation.
Conclusions: Intrathecal baclofen improved functional intelligibility of speech in a carefully selected subject. The Assessment of Intelligibility of Dysarthric Speech was found to be a useful quantitative tool to assess the effect of intrathecal baclofen on spastic dysarthria.
2 Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B, Kroin JS. Intrathecal baclofen for severe spinal spasticity. N Engl J Med1989; 320: 1517-1521.
3.
3 Dralle D, Muller H, Zierski J, Klug N. Intrathecal baclofen for spasticity. Lancet1985; 2: 1003-1003.
4.
4 Albright AL, Cervi A, Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA1991; 265: 1418-1422.
5.
5 Butler C, Campbell S. Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. AACTDM Treatment Outcomes Committee Review Panel. Dev Med Child Neurol2000; 42: 634-645.
6.
6 Albright AL, Barry MJ, Shafton DH, Ferson SS. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol2001; 43: 652-657.
7.
7 Bjornson KF, McLaughlin JF, Loeser JD, Nowak-Cooperman KM, Russel M, Bader KA, Desmond SA. Oral motor, communication, and nutritional status of children during intrathecal baclofen therapy: a descriptive pilot study. Arch Phys Med Rehabil2003; 84: 500-506.
8.
8 Jarrett L, Leary SM, Porter B et al. Managing spasticity in people with multiple sclerosis: a goaloriented approach to intrathecal baclofen therapy. Int J MS Care2001; 3: 2-2.
9.
9 Mason C, Gilpin P, McGowan S, Rossiter D. The effect of intrathecal baclofen on functional intelligibility of speech. Int J Lang Commun Disord1998; 33(suppl): 24-25.
11 Pennington L, Goldbart J, Marshall J. Speech and language therapy to improve the communication skills of children with cerebral palsy. Cochrane Database Syst Rev2004; 2: CD003466-CD003466.
12.
12 Yorkston KM, Beukelman DR. Communication efficiency of dysarthric speakers as measured by sentence intelligibility and speaking rate. J Speech Hear Disord1981; 46: 296-301.
